Ionis Pharmaceuticals (IONS) Receiving Somewhat Favorable Press Coverage, Analysis Shows

News stories about Ionis Pharmaceuticals (NASDAQ:IONS) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.6620932673576 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:

Ionis Pharmaceuticals (IONS) traded down $0.58 during mid-day trading on Thursday, reaching $53.17. The company had a trading volume of 759,742 shares, compared to its average volume of 898,009. The stock has a market capitalization of $6,610.00, a PE ratio of 379.79 and a beta of 2.86. Ionis Pharmaceuticals has a 12-month low of $37.26 and a 12-month high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

Several brokerages have recently issued reports on IONS. BMO Capital Markets lifted their price objective on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a research note on Sunday, September 17th. Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Stifel Nicolaus reiterated a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Finally, Morgan Stanley lifted their price objective on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $50.76.

In related news, Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $52.01, for a total transaction of $572,110.00. Following the completion of the sale, the chairman now owns 48,014 shares in the company, valued at $2,497,208.14. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The stock was sold at an average price of $59.46, for a total value of $981,090.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,549 shares of company stock valued at $7,210,500. 2.13% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Ionis Pharmaceuticals (IONS) Receiving Somewhat Favorable Press Coverage, Analysis Shows” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2018/01/12/ionis-pharmaceuticals-ions-receiving-somewhat-favorable-press-coverage-analysis-shows.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply